Volume 131, Issue 2



January 11, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Kinetics of NK-cell recovery after haploidentical HSCT with posttransplant cyclophosphamide. See the article by Russo et al.

R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
Lamy and colleagues performed a randomized trial of patients with nonbulky limited-stage diffuse large B-cell lymphoma to determine the impact of post–rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) radiation therapy (RT) on outcomes. They demonstrate that adding postremission RT has no impact on progression-free or overall survival.

Human NOTCH4 is a key target of RUNX1 in megakaryocytic differentiation
RUNX1 mutations are known to cause a familial platelet disorder (FPD) characterized by abnormal platelet number and function. Li et al use induced pluripotent stem cells from FPD and corrected platelets to demonstrate that RUNX1 functions in normal hematopoiesis by negatively regulating NOTCH4, indicating a potential pathway for increasing platelet production in vivo and in vitro.

Inhibition of heme oxygenase ameliorates anemia and reduces iron overload in β-thalassemia mouse model
Patients with β-thalassemia intermedia suffer from iron overload despite not requiring transfusion. Garcia-Santos and colleagues demonstrate in a mouse model of β-thalassemia intermedia, inhibition of heme oxygenase ameliorates anemia and decreases iron overload, suggesting potential clinical benefit from suppression of heme metabolism in patients with β-thalassemia intermedia.

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett et al report modest response of relapsed/refractory follicular lymphoma with the Burton’s tyrosine kinase inhibitor ibrutinib, with inferior responses in patients refractory to rituximab.

Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma
Katakoka and colleagues correlate genotyping data from over 400 patients with disease phenotypes and clinical outcomes in adult T-cell leukemia/lymphoma. These data lay the groundwork for developing algorithms to stratify patients and identify potential targeted therapies.

NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications
The use of posttransplant cyclophosphamide (PTC) has widened the availability of hematopoietic stem cell transplantation (HSCT). Russo et al report on the impact of PTC on natural killer cell recovery, with important implications for graft-versus-host disease and graft-versus-leukemia.

How I manage monoclonal gammopathy of undetermined significance
Go and Rajkumar discuss the diagnosis and appropriate follow-up of monoclonal gammopathy of undetermined significance in the context of 7 illustrative cases.


View this week's complete table of contents

Why Submit to Blood?


Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.